Hormonal
HIV protease inhibitor (PI) therapy causes lipodystrophy in HIV-infected patients, characterized by peripheral fat loss and truncal fat accumulation, along with metabolic abnormalities including insulin resistance and dyslipidemia.
If you are taking HIV protease inhibitors, be aware that you may experience changes in body fat distribution (loss in face/limbs, gain in abdomen/neck) and metabolic issues like insulin resistance. Regular monitoring of lipids and glucose is recommended. Do not stop your medication due to these changes without consulting your doctor, as the benefits of HIV suppression usually outweigh the side effects.
such therapy is associated with a lipodystrophy syndrome characterized by selective loss of sc fat from the face and extremities and, in some patients, accumulation of fat around the neck, dorsocervical region, abdomen, and trunk. Lipodystrophy in HIV-infected patients (LDHIV) is associated with insulin resistance and its metabolic complications such as impaired glucose tolerance, diabetes, hypertriglyceridemia and low serum high density lipoprotein cholesterol levels. PIs appear to be the strongest link to LDHIV
Why this rating
Based on a clinical review of multiple observational studies and case reports, not a single RCT.
Source
Lipodystrophy in Human Immunodeficiency Virus-Infected Patients
Dali Chen et al. · The Journal of Clinical Endocrinology & Metabolism · 2002
DOI 10.1210/jc.2002-020794
More from this paper
- Substituting protease inhibitors with other antiretroviral drugs (such as nevirapine) can mitigate metabolic abnormalities like dyslipidemia and glucose intolerance, though reversal of fat redistribution is uncertain.Moderate
- Increased physical activity and dietary restriction can reduce fat accumulation and improve metabolic complications in HIV patients with lipodystrophy.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →